TCM Biotech International Corp. (4169.TW) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
121.50 TWD
Market cap
8.04 bn TWD
P/E (2025)
374.37
P/S (2025)
11.72
Dividend yield
0.26 %
Net margin
2.80 %
Return on equity (ROE)
1.82 %
Return on assets (ROA)
1.59 %

TCM Biotech International Corp. financials

Fiscal year20242025
Revenue666.53 m TWD685.49 m TWD
Gross profit327.31 m TWD296.68 m TWD
Operating income10.01 m TWD18.65 m TWD
EBIT26.62 m TWD18.65 m TWD
Net income21.01 m TWD19.17 m TWD
Diluted EPS – continuing operations0.36 TWD0.32 TWD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About TCM Biotech International Corp.

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabetic. It also provides medical detection platform for breast cancer recurrent risk detection and postoperative detection platform for liver cancer, as well as philips non-invasive positive pressure ventilation and accessories. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.